MARC Record from marc_columbia

LEADER: 03885cam a2200397Ii 4500
001 14345245
005 20191017103414.0
008 191015t20192019dcua 000 0 eng d
035 $a(OCoLC)on1123171340
040 $aNRC$beng$cNRC$erda
020 $a9780309490863
020 $a0309490863
035 $a(OCoLC)1123171340
050 04 $aRC268.3$b.N385 2019
049 $aZCUA
110 2 $aNational Academies of Sciences, Engineering, and Medicine (U.S.),$eauthor.
245 10 $aAdvancing progress in the development of combination cancer therapies with Immune checkpoint Inhibitors :$bproceedings of a workshop /$cErin Balogh and Sharyl J. Nass, rapporteurs; National Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division, the National Academies of Sciences, Engineering, Medicine.
264 1 $aWashington, D.C. :$bNational Academies Press,$c2019.
300 $axx, 67 pages:$bcolor illustrations ;$c23 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
504 $aIncludes bibliographical references.
505 0 $aAcronyms and Abbreviations -- Proceedings of the workshop -- Workshop overview -- The landscape for immune checkpoint inhibitor therapy -- Strategies for combinations with PD-1/PD-LI inhibitors -- Biomarkers in development or in use for immune checkpoint inhibitor therapies -- Clinical trial design strategies for combination immunotherapy -- Real-world data -- Wrap-up -- References -- Appendix A: Statement of task -- Appendix B: Workshop agenda.
520 $a"In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g., cancer cells, microorganisms). However, cancer cells can coopt these "checkpoint" proteins and thwart the immune system's ability to recognize and attack cancer cells. To help promote an immune response to cancer, researchers have developed immune checkpoint inhibitors that enable T-cells to recognize cancer cells as foreign and to prevent deactivation of an immune system response. To examine the challenges and opportunities to develop combination cancer therapies that include immune checkpoint inhibitors, the National Cancer Policy Forum held a workshop on July 16-17, 2018, in Washington, DC. This workshop convened stakeholders with a broad range of expertise, including cancer researchers, clinicians, patient advocates, and representatives from industry, academia, and government. This publication summarizes the presentations and discussions from the workshop"--Publisher's description
650 0 $aChemotherapy, Combination$vCongresses.
650 0 $aCancer$xTreatment$vCongresses.
650 0 $aCancer$xImmunotherapy$vCongresses.
650 0 $aCancer$xChemotherapy$vCongresses.
650 0 $aCancer$xImmunological aspects.
700 1 $aNass, Sharyl J.$erapporteur.
700 1 $aBalogh, Erin,$erapporteur.
710 2 $aNational Cancer Policy Forum (U.S.),$eissuing body.
711 2 $aAdvancing Progess in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors (Workshop)$d(2018:$cWashington, D.C.),$jauthor.
776 08 $iOnline version:$aNational Academies of Sciences, Engineering, and Medicine$tAdvancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors.$dWashington, D.C. : National Academies Press,$c2019$z9780309490863$w(OCoLC)1119610240
852 00 $boff,sci$hRC268.3$i.N285 2019g